Abstract
Post-embolisation syndrome (PES) is a prevalent complication that occurs in patients following uterine artery embolisation (UAE) for the treatment of uterine fibroids. The aetiology of PES remains incompletely understood, although postulated to result secondary to tissue infarction resulting in release of inflammatory mediators. We followed PRISMA guidelines and performed a systematic review of studies of PES following UAE from inception to October 2022. Our published protocol was prospectively registered. Our search yielded 54 results. We reviewed 22 full texts, and nine articles were included. Observational studies comprised 6/9 relevant studies, with 5/9 retrospective design. The rate of PES was documented in 5/8 studies (excluding case report) with a reported incidence ranging from 4–34.6%. Five of the nine studies studies postulated that the aetiological basis of PES is inflammatory related. Further research is necessary to advance our understanding of PES to define the biological basis of the syndrome with more certainty and gain a consensus on peri-procedure management to reduce incidence and improve patient outcomes.
Keywords: uterine artery embolization, post-embolisation syndrome, fibroids, inflammation
1. Introduction
Uterine fibroids are the most prevalent benign gynaecological tumour [1]. The exact aetiology determining the maturation and regression of fibroids remains elusive, although their growth is known to be triggered by sex steroid hormones [2]. Fibroids are generally diagnosed in the later reproductive period, with a reported incidence of 70% in white women and in excess of 80% in black women [1], whilst they regress in post-menopausal women, likely due to the ovaries producing diminishing levels of oestrogen [2]. Symptomatic fibroids can have a detrimental negative impact on patient quality of life (QoL) including frequent pressure pain, subfertility and more commonly heavy or prolonged menstrual bleeding [1,3]. In the United Kingdom, the National Institute of Clinical Excellence have reported that over one million women pursue medical attention for heavy menstrual bleeding per annum [4], with costs (direct and indirect) for uterine fibroids estimated at 34.4 billons dollars per annum in the United States [1].
Treatment of uterine fibroids is generally reserved for women who are either symptomatic or those with large fibroids who are planning pregnancy [3]. To date, no medical treatment for fibroids has demonstrated prolonged efficacy with acceptable safety data [1]. Gonadotrophin-releasing hormone analogues are effective at reducing the size of fibroids, however, prolonged use is limited by their negative effect on bone mineral density [1]. Surgical management of symptomatic fibroids is common, with a reported 30% of annual hysterectomies in the United States performed which is the second most common indication [3], with major adverse sequelae occurring in an estimated 7% of post hysterectomy [5].
Uterine artery embolization (UAE) is a minimally invasive procedure, which was initially described in 1995 as a successful alternative to surgery and hormonal treatment for symptomatic uterine fibroids [6]. In UAE, the uterine arteries and their branches bilaterally are occluded with particulate emboli, with the aim of inducing ischaemic necrosis of the fibroids, without resultant permanent negative sequalae on the otherwise normal uterus [1]. UAE is effective in reducing the symptomatology of treated women, with a reported 69% of women undergoing a technical successful procedure (avoiding a hysterectomy) and comparable QoL to hysterectomy after 10 years [7]. However, concerns remain regarding potential complications including post-embolisation syndrome, post procedure pain, infection, premature ovarian failure and secondary amenorrhoea [7,8,9]. UAE is a uterine preserving procedure, thereby an attractive potential option for subfertile women with large fibroids [9].
Post-embolisation syndrome (PES) following UAE is an iatrogenic phenomenon, which usually commences in the first 24 to 48 h post-procedure and resolves spontaneously over 10–14 days [10]. It is characterised by pelvic pain, low grade fever, myalgia, mild leucocytosis and discharge [11]. Current treatment entails supportive measures with pain relief, antiemetics, anti-inflammatory medications and hydration. With effective symptom control, patients are usually discharged within 24 h [3]. Diagnosis can be difficult, often requiring extensive investigations before confirmation, in order to exclude more sinister differentials including sepsis [12]. Previous studies performed on a related phenomenon post-ablation syndrome following hepatic and renal ablation treatment reported an incidence of 33% (12/36), with significant pain and interference with QoL [13].
The aim of this systematic review is to assess the available literature regarding the burden and management of PES in women post UAE.
2. Materials and Methods
2.1. Selection Criteria
A systematic review was performed according to published guidelines from the Cochrane Collaboration [14] and is reported according to the PRISMA guidelines [15]. A study protocol (Supplementary Table S1) was developed to include original research articles presenting data related post-embolisation syndrome from uterine artery embolisation. Studies involving post-operative complications and their management were included. All published observational studies and randomized trials were included if they met the following criteria: contained original data, human subjects, printed in English language, and full text was available. No date restrictions were applied.
2.2. Search Strategy
A systematic search of the literature was performed MEDLINE (PubMed), Cochrane and Embase databases. The databases were searched from inception to October 2022. The search was performed using key terms (Post-embolisation syndrome*) AND ((Uterine artery [title/abstract]) OR (Uterine fibroid)) (Appendix A). Two reviewers (M.W. and OJOC) independently screened titles and abstracts using the Rayyan web application for systematic review screening [16]. Full texts were sourced for relevant articles and Zotero used as our reference manager. Inclusion criteria were assessed independently (M.W. and OJOC), and the final list was agreed by consensus. A manual search of the reference lists of identified articles was performed. The systematic review was performed in accordance with the pre-specified protocol, which was prospectively registered on PROSPERO (CRD42022365162), the international prospective register of systematic reviews.
2.3. Data Extraction
For each study, the following data were collected:
-
(a)
Title, journal, year of publication, country of origin study
-
(b)
Study design and data collection (prospective or retrospective)
-
(c)
Inclusion, exclusion criteria
-
(d)
Study population number and demographics
-
(e)
Type and indication for intervention
-
(f)
Outcome measures: aetiology, post-procedure complications and clinical outcomes
2.4. Quality Assessment
The Effective Public Health Practice Project (EPHPP) quality assessment tool was utilised to analysis quality of included studies [17]. Quality areas assessed included study design, bias and study blinding, confounder management, data collection methods, intervention integrity and analysis. The EPHPP tool was used to grade each component, with each study then categorised as strong, moderate, or weak quality.
3. Results
3.1. Study Selection
A total of 54 articles were identified through electronic database searches and assessed for eligibility, with 41 remaining following removal of duplicates. We removed 19 papers following abstract review (four review articles and 15 not related to UAE), with eligible studies remaining for full-text review. A further 13 were removed on full-text review as five studies had no full texts available (conference abstracts), three had no outcome data related to UAE safety, incidence of PES or the aetiological basis of the complication. Nine studies remained for final analysis after full text assessment [3,8,9,10,18,19,20,21,22]. The screening process is described in Figure 1.
Figure 1.
PRISMA flow of studies included in our review.
3.2. Study Characteristics
The salient characteristics of included papers are described in Table 1 and Table 2. Observational studies comprised the majority of relevant studies (6/9), with 5/9 retrospective in design. The rate of PES was documented in 5/8 studies (excluding case report) ranging from 4–34.6%. 5/9 studies suggest an inflammatory aetiology of PES.
Table 1.
Demographic information of included studies.
| Author | Year | Country | Study Type | Number of Studies |
|---|---|---|---|---|
| Sabre [18] | 2021 | USA | Retrospective, Observational |
62 |
| Prollius [9] | 2004 | S. Africa | Prospective Case-control | 63 |
| Bilhim [19] | 2010 | Portugal | Retrospective, Observational |
900 |
| Leonhardt [10] | 2004 | Sweden | Retrospective, Observational (Case Report) | 1 |
| Salehi [8] | 2015 | Iran | Prospective, Observational |
65 |
| REST [3] | 2007 | UK | Prospective RCT | 157 (106 UAE group) |
| Pisco [20] | 2009 | Portugal | Retrospective, observational | 234 |
| Ganguli [21] | 2008 | USA | Retrospective, observational | 78 |
| Ruuskanen [22] | 2009 | Finland | Prospective Clinical trial | 62 |
Table 2.
Aims, results, incidence and aetiology of PES of included studies.
| Author | Aim | Results | Embolisation Substance | PES Rate, n (%) | Aetiological Basis PES |
Assessment Grade |
|---|---|---|---|---|---|---|
| Sabre [18] | Assess predictive value of neutrophils, lymphocytes, platelets, neutrophils to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR) in identifying the occurrence of PES post UAE | Patients with a preprocedural platelet count less than 336 × 103/uL were less likely to have PES | Not specified | 12/62 (19.4) | Inflammatory | Moderate |
| Prollius [9] | Compare the efficacy of UAE for large versus standard fibroids | Large uterus does not decrease UAE’s efficacy | Polyvinyl alcohol (2–300 mg) | 18/51 (34.6) in in standard group, 3/12 (25.0) in large fibroids | None documented | Weak |
| Bilhim [19] | Assess NSAIDs in the management of the post-embolization symptoms | NSAID enables good control of the post-embolization symptoms | Non-spherical polyvnyl alcohol (dose unknown) | None documented | Inflammatory | Weak |
| Leonhardt [10] | Case report of common and expected reactions such as PES | PES on day 1 post-op, resolved by day 2 | Polyvinyl alcohol (355–500 μm) | 1/1 (100.0) | Inflammatory | Weak |
| Salehi [8] | Evaluate the efficacy and complications of UAE in patients with symptomatic uterine fibroids | UAE was a successful treatment for uterine fibroids that preserved the uterus, had minimal complications, and required short hospitalization and recovery | Polyvinyl alcoholol with or without gel foam (88.7%), Embo-Gold (8.1%) and Embosphere (3.2%) (dose unknown) | 5/65 (7.7) | None documented | Moderate |
| REST [3] | Compare UAE to surgery in women with symptomatic uterine fibroids. Assess QoL after 1 year | Comparable QoL between groups. Faster recovery time in UAE group (1v 5 days). Major complication one year post UAE requiring further intervention 3/106 | Not specified | 26/106 (24.5) | None documented | Strong |
| Pisco [20] | Evaluated safety of UAE as an outpatient procedure | Pre-operative medication commenced on the day before UAE allow to be performed safely as an outpatient | Non-spherical polyvinyl alcohol particles (500–700 μm) | None documented | None documented | Moderate |
| Ganguli [21] | To assess for association between leucocytosis and PES | Clinically defined leukocytosis presented in 21% of all patients undergoing elective UAE first day post procedure | Not specified | 16/65 (21) | Inflammatory | Moderate |
| Ruuskanen [22] | Evaluate uterine ischaemia after uterine artery embolisation (UAE) using magnetic resonance imaging | Selective embolisation may result in a therapeutic effect with fewer side effects | EmboSphere (550–700 μm) | None documented | Inflammatory | Moderate |
3.3. Quality Assessment
EPHPP quality assessment tool was used to analyse each included study. Of the seven included studies, one defined as “strong”, five as “moderate” and three as weak.
3.4. Characteristics of Fibroids from Studies
The salient characteristics of fibroids identified in included papers are described in Table 3. The major type of fibroid was stated in 4/9 studies. The mean fibroid size was listed in 6/9 studies.
Table 3.
Characteristics of fibroids.
| Author | Type (%) | Mean Size (cm3) |
|---|---|---|
| Sabre [18] | Intramural (30.6); subserosal (16.1;) submucosal (16.1); mixed (37.1) | 414.7 (PES+) 904.8 (PES−) |
| Prollius [9] | Not specified | Unknown (>780 (n = 12) <780 (n = 49)) |
| Bilhim [19] | Not specified | Unknown |
| Leonhardt [10] | Submucosal | 86.63 |
| Salehi [8] | Intramural (80.6); Submucosal (14.5); Subserosal (4.8) | Unknown |
| REST [3] | Not specified | 579 |
| Pisco [20] | Intramural (76.1); Submucosal (10.7); Subserosal (13.2) | 110.5 |
| Ganguli [21] | Not Specified | Unknown |
| Ruuskanen [22] | Not specified | 200 |
4. Discussion
4.1. Aetiology and Potential Biomarkers
The aetiology of post-embolisation syndrome (PES) following uterine artery embolization (UAE) remains incompletely understood. It has been postulated to result from the release of degradation products, inflammatory and vasoactive mediators including interleukin-6 and tumour necrosis factor- α following necrosis and infarction of tissue [10,19]. The release of ischaemic fibroid products into the vascular system can result in a swinging fever, pelvic or abdominal pain plus or minus nausea and vomiting. This is commonly followed by leucopenia, leukocytosis and possible increased C-reactive protein. Further clinical studies are necessary to characterize the specific underlying mechanism pertaining to the syndrome [21,23]. Despite a paucity of studies concerning the specifics of the mechanism underlying PES, the current literature provides several observations that support the hypothesis of an inflammatory aetiology [19,20]. Additionally, previous literature has demonstrated that pain level correlates with volume and percentage of ischaemic myometrial tissue, suggesting a potential relationship between fibroid size and the severity of PES symptoms.
Sabre et al. assessed the predictive values of neutrophils, lymphocytes, platelets, neutrophils to lymphocytes ratio (NLR) and platelets to lymphocytes ratio (PLR) to highlight the occurrence of PES after UAE [18]. Sixty-two patients were recruited, of whom 19.4% (12/62) developed PES. The researchers reported a statistically significant elevation in platelets in the PES group (p = 0.036), concluding that platelet levels may be significant when it comes to predicting adverse outcomes [18]. Futhermore, Ganguli et al. investigated the association of leucocytosis as a component of PES in the absence of infectious aetiology. They reported an incidence of leucocytosis in 21% of patients with PES beyond the over the first day post-procedure [21]. This is a challenge in diagnosing PES, as it must be differentiated from more sinister causes such as bacterial sepsis and tumour lysis syndrome.
Magnetic resonance imaging has been utilised to assess uterine ischemia after UAE. Ruuskanen et al. aimed to evaluate the role of myometrial and fibroid ischemia in the pathogenesis of the pain experienced after UAE. They determined that patients who suffered a high level of pain tended to have moderate to severe myometrial ischaemia, however the extent of fibroid ischaemia did not correlate with patient experienced pain [22]. UAE of large fibroids was previously reported to increase the risk of the patient suffering PES [24]. However, Prollius et al. highlighted contradictory findings in a study of 61 women, 12 with a uterus greater than 780 cm3 and 49 with a uterus less than 780 cm3 as measured on ultrasound. They reported comparable efficacy and complications including incidence of PES [9].
4.2. Perioperative Management
The peri-procedural medical management for UAE is highly variable. Bilhim et al. supported an inflammatory origin for PES by evaluating the utilization of non-steroidal anti-inflammatory drugs (NSAIDS) in the management of PES symptoms. In this study, they administered NSAIDs pre-procedure, during the procedure and post UAE via a variety of routes (oral, intravenous or intra-arterially) [19]. Overall the researchers concluded that the utilization of NSAIDs during UAE reduced patient reported symptomatology of PES including abdominal discomfort and pyrexia [19]. In addition, at the same institution Pisco et al. evaluated whether UAE could be safely performed as an outpatient procedure, evaluating 234 patients who underwent UAE [20]. The included patients commenced treatment with a NSAID, an acid-suppressing drug, an anti-histamine, and a laxative one day prior to their procedure. Post-procedural pain scores were assessed at several intervals including the evening of UAE, prior to hospital discharge and following discharge. The mean pre-procedure pain scores were 0.9, increasing to 2.5 four to eight hours post-procedure, before falling to 0.9 at discharge. In this study, the entire cohort were discharged within eight hours following embolisation. Bilhim et al. concluded that UAE can be performed safely as an outpatient procedure and utilization of a peri-procedural medication regimen including a NSAID can significantly reduce patient post-procedural pain [20]. These two studies may also serve to support further an inflammatory aetiology [19,20].
Several studies report rapid recovery following PES post UAE, in addition to shortened hospital stay compared to hysterectomy [3,8]. The REST study group noted a mean hospital stay reduction of four days compared to surgery, although 3/106 patients required further admissions over the post-procedure year [3].
4.3. Clinical Significance
PES is a frequently occuring sequelae of UAE. Data specifically related to the incidence and aetiology of PES post embolisation of the uterine artery is limited. Overall the incidence of PES was found to range from 19.4% to 34.5%, which was similar to previously reported PES rate following embolisation of the prostatic artery [23]. The heterogenicity between the studies made the rate difficult to interpret. We believe, that this rate is likely to be underestimated given the overlap of symptoms with alterative diagnoses such as in infection. Additionally, the syndrome can occur up to one week post-procedure, thus patient may be discharge making recognition more difficult.
4.4. Strengths and Limitations of the Study
The primary strength of the present study is that independent screening and abstraction for was performed, resulting in the largest systematic review on the topic to our knowledge. However, there were several limitations including small study number of studies available on the topic of PES specific to UAE, with only five studies referring to the potential aetiological basis of the syndrome and six related to the incidence of the syndrome. Furthermore, there was heterogeneity in reporting of study aims and outcomes as exist with all systematic reviews. Three studies do not report embolic agent utilised, whilst the remaining six used a variety of agents. Two prospective clinical trials were identified, but neither aimed to assessed specifically the aetiological basis of PES.
5. Conclusions
PES is the most common adverse event and frequent indication for hospitalization following UAE, yet it is a poorly understood phenomenon with a relative paucity of literature to date. The systematic review highlighted limited studies, whilst there was heterogeneity of reporting outcomes, including those related to aetiology and incidence of PES. Further research is necessary to advance our understanding of PES to define the biological basis of the syndrome with more certainty and consensus on peri-procedure management to reduce incidence and improve patient outcomes.
Acknowledgments
The corresponding author certifies that no other persons have made substantial contributions to the research and/or manuscript.
Abbreviations
EPHPP—Effective Public Health Practice Project; NSAID—Non-steroidal anti-inflammatory drug; NLR—neutrophils to lymphocytes ratio; PLR—platelets to lymphocytes ratio; PES: Post-embolisation syndrome; QoL: quality of life; RCT—randomized controlled trial; UAE: uterine artery embolization.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12122916/s1, Table S1: Study Protocol.
Appendix A. Electronic Database Search Terms
MEDLINE (Pubmed)
((post embolisation syndrome) OR (post embolisation syndrome)) AND ((uterine artery[Title/Abstract]) OR (uterine fibroid[Title/Abstract]))
EMBASE
(‘post embolization syndrome’/exp OR ‘post embolization syndrome’) AND (‘uterine artery’:ab,ti OR ‘uterine fibroid’:ab,ti)
Cochrane
(“post-embolisation syndrome”) AND ((“uterine artery”) OR (“Uterine fibroid”))
Author Contributions
M.G.W., M.M.B., M.M.M., O.J.O. and A.T.O. were responsible for conceptualisation and methodology. M.G.W. and O.J.O. were responsible for data collection, data interpretation and critical revision of the report. M.G.W. and Y.W.K. were responsible for writing report. M.G.W., S.M.O., S.P.P., L.S. and O.E.O. were responsible for review and editing. All authors were responsible for critical review of final report. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
No known conflict of interests to declare by all authors.
Funding Statement
This research received no external funding.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Giuliani E., As-Sanie S., Marsh E.E. Epidemiology and management of uterine fibroids. Int. J. Gynecol Obstet. 2020;149:3–9. doi: 10.1002/ijgo.13102. [DOI] [PubMed] [Google Scholar]
- 2.Reis F.M., Bloise E., Ortiga-Carvalho T.M. Hormones and pathogenesis of uterine fibroids. Best Pract. Res. Clin. Obs. Gynaecol. 2016;34:13–24. doi: 10.1016/j.bpobgyn.2015.11.015. [DOI] [PubMed] [Google Scholar]
- 3.Edwards R.D., Moss J.G., Lumsden M.A., Wu O., Murray L.S., Twaddle S., Murray G.D. Uterine-Artery Embolization versus Surgery for Symptomatic Uterine Fibroids. N. Engl. J. Med. 2007;356:360–370. doi: 10.1056/NEJMoa062003. [DOI] [PubMed] [Google Scholar]
- 4.National Institute of Clinical Excellance Uterine Artery Embolisation for Fibroids. Interv Proced Guid IPG367. 2010. [(accessed on 13 October 2022)]. Available online: https://www.nice.org.uk/guidance/ipg367.
- 5.Settnes A., Moeller C., Topsoee M.F., Norrbom C., Kopp T.I., Dreisler E., Joergensen A., Dueholm M., Rasmussen S.C., Froeslev P.A., et al. Complications after benign hysterectomy, according to procedure: A population-based prospective cohort study from the Danish hysterectomy database, 2004–2015. BJOG Int. J. Obs. Gynaecol. 2020;127:1269–1279. doi: 10.1111/1471-0528.16200. [DOI] [PubMed] [Google Scholar]
- 6.Ravina J.H., Merland J.J., Ciraru-Vigneron N., Bouret J.M., Herbreteau D., Houdart E. Arterial embolization: A new treatment of menorrhagia in uterine fibroma. Presse Med. Paris Fr. 1983. 1995;24:1754. [PubMed] [Google Scholar]
- 7.de Bruijn A.M., Ankum W.M., Reekers J.A., Birnie E., van der Kooij S.M., Volkers N.A. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am. J. Obs. Gynecol. 2016;215:745.e1–745.e12. doi: 10.1016/j.ajog.2016.06.051. [DOI] [PubMed] [Google Scholar]
- 8.Salehi M., Jalilian N., Salehi A., Ayazi M. Clinical Efficacy and Complications of Uterine Artery Embolization in Symptomatic Uterine Fibroids. Glob. J. Healthy Sci. 2015;8:245–250. doi: 10.5539/gjhs.v8n7p245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Prollius A., de Vries C., Loggenberg E., du Plessis A., Nel M., Wessels P.H. Uterine artery embolisation for symptomatic fibroids: The effect of the large uterus on outcome. BJOG Int. J. Obs. Gynaecol. 2004;111:239–242. doi: 10.1046/j.1471-0528.2003.00019.x. [DOI] [PubMed] [Google Scholar]
- 10.Leonhardt H., Aziz A., Lönn L. Post-embolization syndrome and complete expulsion of a leiomyoma after uterine artery embolization. Acta Obs. Gynecol. Scand. 2005;84:303–305. doi: 10.1111/j.0001-6349.2005.0358d.x. [DOI] [PubMed] [Google Scholar]
- 11.Schirf B.E., Vogelzang R.L., Chrisman H.B. Complications of Uterine Fibroid Embolization. Semin. Interv. Radiol. 2006;23:143–149. doi: 10.1055/s-2006-941444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Szkodziak P., Pyra K., Szkodziak F., Krzyżanowski J., Czuczwar P., Woźniak S., Jargiełło T., Paszkowski T. The Lublin Protocol of the Uterine Arteries Embolization in the Treatment of Symptomatic Uterine Fibroids. [(accessed on 13 October 2022)];JoVE. 2020 163 doi: 10.3791/61530. Available online: https://pubmed.ncbi.nlm.nih.gov/33016950/ [DOI] [PubMed] [Google Scholar]
- 13.Wah T.M., Arellano R.S., Gervais D.A., Saltalamacchia C.A., Martino J., Halpern E.F., Maher M., Mueller P.R. Image-guided Percutaneous Radiofrequency Ablation and Incidence of Post–Radiofrequency Ablation Syndrome: Prospective Survey. Radiology. 2005;237:1097–1102. doi: 10.1148/radiol.2373042008. [DOI] [PubMed] [Google Scholar]
- 14.Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J. In: Cochrane Handbook for Systematic Reviews of Interventions. Welch V.A., editor. Cochrane; London, UK: 2022. [(accessed on 13 October 2022)]. version 6.3; (updated February 2022) [Internet] Available online: www.training.cochrane.org/handbook. [Google Scholar]
- 15.Moher D. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009;151:264. doi: 10.7326/0003-4819-151-4-200908180-00135. [DOI] [PubMed] [Google Scholar]
- 16.Ouzzani M., Hammady H., Fedorowicz Z., Elmagarmid A. Rayyan—A web and mobile app for systematic reviews. Syst. Rev. 2016;5:210. doi: 10.1186/s13643-016-0384-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Thomas B.H., Ciliska D., Dobbins M., Micucci S.A. Process for systematically reviewing the literature: Providing the research evidence for public health nursing interventions. Worldviews Evid. Based Nurs. 2004;1:176–184. doi: 10.1111/j.1524-475X.2004.04006.x. [DOI] [PubMed] [Google Scholar]
- 18.Sabre A., Sisti G., Arruarana V.S., Alexander G., Upadhyay R. Utilization of platelet count in prediction of post-embolization syndrome after uterine artery embolization. J. Gynecol. Obs. Hum. Reprod. 2021;50:102094. doi: 10.1016/j.jogoh.2021.102094. [DOI] [PubMed] [Google Scholar]
- 19.Bilhim T., Pisco J.M. The role of nonsteroidal anti-inflammatory drugs (NSAIDS) in the management of the post-embolization symptoms after uterine artery embolization. Pharmaceuticals. 2010;3:1729–1738. doi: 10.3390/ph3061729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Pisco J.M., Bilhim T., Duarte M., Santos D. Management of Uterine Artery Embolization for Fibroids as an Outpatient Procedure. J. Vasc. Interv. Radiol. 2009;20:730–735. doi: 10.1016/j.jvir.2009.01.029. [DOI] [PubMed] [Google Scholar]
- 21.Ganguli S., Faintuch S., Salazar G.M., Rabkin D.J. Postembolization Syndrome: Changes in White Blood Cell Counts Immediately after Uterine Artery Embolization. J. Vasc. Interv. Radiol. 2008;19:443–445. doi: 10.1016/j.jvir.2007.11.021. [DOI] [PubMed] [Google Scholar]
- 22.Ruuskanen A., Sipola P., Hippeläinen M., Wüstefeld M., Manninen H. Pain after uterine fibroid embolisation is associated with the severity of myometrial ischaemia on magnetic resonance imaging. Eur. Radiol. 2009;19:2977–2985. doi: 10.1007/s00330-009-1481-8. [DOI] [PubMed] [Google Scholar]
- 23.Svarc P., Taudorf M., Nielsen M.B., Stroomberg H.V., Røder M.A., Lönn L. Postembolization Syndrome after Prostatic Artery Embolization: A Systematic Review. Diagnostics. 2020;10:659. doi: 10.3390/diagnostics10090659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kaufman C., Pollak J., Mojibian H. What Is Too Big? Uterine Artery Embolization of a Large Fibroid Causing Abdominal Compartment Syndrome. Semin. Interv. Radiol. 2014;31:207–211. doi: 10.1055/s-0034-1373795. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Not applicable.